Results 101 to 110 of about 56,162 (258)
JAK inhibitors for the treatment of rheumatoid arthritis
Immunological Medicine, 2020 The treatment of rheumatoid arthritis has changed dramatically over the last two decades since the development of biological disease-modifying anti-rheumatic drugs (bDMARDs). Moreover, Janus kinase (JAK) inhibitors became available in 2013.
Akio Morinobu
doaj +1 more source
Protein pyrophosphorylation by inositol pyrophosphates — detection, function, and regulation
FEBS Letters, EarlyView.Protein pyrophosphorylation is an unusual signaling mechanism that was discovered two decades ago. It can be driven by inositol pyrophosphate messengers and influences various cellular processes. Herein, we summarize the research progress and challenges of this field, covering pathways found to be regulated by this posttranslational modification as ...
Sarah Lampe +3 more
wiley +1 more source
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]
, 2019 Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M +4 more
core
Cell wall target fragment discovery using a low‐cost, minimal fragment library
FEBS Letters, EarlyView.LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan +5 more
wiley +1 more source
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer [PDF]
, 2017 Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced tumor suppressor ...
Attwood, Kristopher +16 more
core +3 more sources
Efficacy of JAK inhibitors in Crohn’s Disease [PDF]
Journal of Crohn's and Colitis, 2019 Abstract Inhibition of Janus kinases [JAKs] in Crohn’s disease [CD] patients has shown conflicting results in clinical trials. Tofacitinib, a pan-JAK inhibitor, showed efficacy in ulcerative colitis [UC] and has been approved for the treatment of patients with moderate to severe UC.
openaire +3 more sources
Tofacitinib for Prurigo Nodularis: A Case Report
Clinical, Cosmetic and Investigational Dermatology, 2022 Changlan Peng,1 Chunxiao Li,2 Yingying Zhou,1 Qiuyue Wang,1 Ping Xie,1 Tianhao Li,2,* Pingsheng Hao2,* 1Department of Dermatology, Chengdu University of Traditional Chinese Medicine, Chengdu, People’s Republic of China; 2Department of Dermatology,
Peng C +6 more
doaj
FEBS Letters, EarlyView.We reconstituted Synechocystis glycogen synthesis in vitro from purified enzymes and showed that two GlgA isoenzymes produce glycogen with different architectures: GlgA1 yields denser, highly branched glycogen, whereas GlgA2 synthesizes longer, less‐branched chains.
Kenric Lee +3 more
wiley +1 more source
SAR Studies on the Inhibitors for the Treatment of Inflammatory Diseases [PDF]
, 2016 School of Molecular Sciences(Chemistry)Inflammation is defensive host response that occurs from infection and injury and the inflammatory process is the pivotal physiological response of our body and essential part of the human physiology.
Kim, Min-Jeong
core
Regulation of pancreatic cancer aggressiveness by stromal stiffening [PDF]
, 2016 No abstract ...
A Neesse +13 more
core +1 more source